Pappachan Joseph M, Raskauskiene Diana, Kutty V Raman, Clayton Richard N
Department of Endocrinology (J.M.P., D.R.), Walsall Manor Hospital, West Midlands, WS2 9PS, United Kingdom; Achutha Menon Centre for Health Science Studies (V.R.K.), Sree Chitra Tirunal Institute for Medical Sciences & Technology, Thiruvananthapuram, India 695011; and Keele University Medical School & University Hospital of North Staffordshire (R.N.C.), Stoke-on-Trent, Staffordshire ST4 6QG, United Kingdom.
J Clin Endocrinol Metab. 2015 Apr;100(4):1405-11. doi: 10.1210/jc.2014-3787. Epub 2015 Feb 6.
Several previous observational studies showed an association between hypopituitarism and excess mortality. Reports on reduction of standard mortality ratio (SMR) with GH replacement have been published recently.
This meta-analysis assessed studies reporting SMR to clarify mortality risk in hypopituitary adults and also the potential benefit conferred by GH replacement.
A literature search was performed in Medline, Embase, and Cochrane library up to March 31, 2014.
Studies with or without GH replacement reporting SMR with 95% confidence intervals (95% CI) were included.
Patient characteristics, SMR data, and treatment outcomes were independently assessed by two authors, and with consensus from third author, studies were selected for analysis. Meta-analysis was performed in all studies together, and those without and with GH replacement separately, using the statistical package metafor in R.
Six studies reporting a total of 19 153 hypopituiatary adults with a follow-up duration of more than 99,000 person years were analyzed. Hypopituitarism was associated with an overall excess mortality (weighted SMR, 1.99; 95% CI, 1.21-2.76) in adults. Female hypopituitary adults showed higher SMR compared with males (2.53 vs 1.71). Onset of hypopituitarism at a younger age was associated with higher SMR. GH replacement improved the mortality risk in hypopituitary adults that is comparable to the background population (SMR with GH replacement, 1.15; 95% CI, 1.05-1.24 vs SMR without GH, 2.40; 95% CI, 1.46-3.34). GH replacement conferred lower mortality benefit in hypopituitary women compared with men (SMR, 1.57; 95% CI, 1.38-1.77 vs 0.95; 95% CI, 0.85-1.06).
There was a potential selection bias of benefit of GH replacement from a post-marketing data necessitating further evidence from long-term randomized controlled trials.
Hypopituitarism may increase premature mortality in adults. Mortality benefit from GH replacement in hypopituitarism is less pronounced in women than men.
此前多项观察性研究显示垂体功能减退与死亡率过高之间存在关联。近期已发表了关于生长激素(GH)替代治疗降低标准死亡率(SMR)的报告。
本荟萃分析评估了报告SMR的研究,以阐明垂体功能减退成年患者的死亡风险以及GH替代治疗的潜在益处。
截至2014年3月31日,在Medline、Embase和Cochrane图书馆进行了文献检索。
纳入报告了SMR及95%置信区间(95%CI)的有无GH替代治疗的研究。
两名作者独立评估患者特征、SMR数据和治疗结果,在第三名作者达成共识后,选择研究进行分析。使用R语言中的metafor统计软件包对所有研究一起进行荟萃分析,对未接受和接受GH替代治疗的研究分别进行分析。
分析了6项研究,共纳入19153例垂体功能减退成年患者,随访时间超过99000人年。垂体功能减退与成年患者总体死亡率过高相关(加权SMR为1.99;95%CI为1.21 - 2.76)。垂体功能减退的成年女性的SMR高于男性(2.53对1.71)。垂体功能减退发病年龄较轻与较高的SMR相关。GH替代治疗改善了垂体功能减退成年患者的死亡风险,使其与总体人群相当(接受GH替代治疗的SMR为1.15;95%CI为1.05 - 1.24,未接受GH治疗的SMR为2.40;95%CI为1.46 - 3.34)。与男性相比,GH替代治疗在垂体功能减退女性中带来的死亡获益较低(SMR为1.57;95%CI为1.38 - 1.77对0.95;95%CI为0.85 - 1.06)。
从上市后数据中存在GH替代治疗益处的潜在选择偏倚,需要长期随机对照试验提供进一步证据。
垂体功能减退可能增加成年人过早死亡。垂体功能减退患者接受GH替代治疗的死亡获益在女性中不如男性明显。